胶质母细胞瘤短程与常规放疗随机研究中的毒性剂量学预测因素
基于133例新诊断胶质母细胞瘤患者随机对照试验的剂量学与前瞻性毒性数据,分析危及器官约束与毒性及认知功能的关系。短程组毒性未显著增加,方案允许的最大剂量内危及器官受量与无≥2级毒性相关,左侧海马平均剂量与放疗后简易精神状态检查评分下降显著相关。
要点
- 短程组与常规组相比毒性事件未显著增加。
- 危及器官剂量在方案允许最大剂量内与无≥2级毒性相关(p<0.001)。
- 左侧海马平均剂量与放疗后简易精神状态检查评分下降显著相关(p=0.005),右侧未达统计学显著(p=0.277)。
核心结论
- 在本试验中,方案危及器官约束适用于限制常规和短程辅助放化疗治疗胶质母细胞瘤的≥2级毒性。
- 较高的左侧海马平均剂量可预测放疗后神经认知功能下降。
- 推荐常规勾画并使用剂量约束限制海马剂量,以尽量减少接受放化疗的胶质母细胞瘤患者的神经认知功能下降。
研究设计与样本
- 数据来自一项随机对照试验,纳入133例年龄18-70岁、ECOG体能评分0-2的新诊断胶质母细胞瘤成人患者。
- 患者接受60 Gy/30次(常规组)对比20次(短程组)辅助放化疗(ClinicalTrials.gov标识符:NCT02206230)。
- 将实际计划对危及器官的剂量学与前瞻性收集的毒性和简易精神状态检查数据相关联。
主要发现
- 短程组与常规组相比毒性事件未显著增加。
- 在两个治疗组中,所有危及器官的受照剂量在方案允许最大剂量内与无≥2级毒性相关(p<0.001)。
- 在两个治疗组中,所有检查的危及器官剂量达到或超过方案限值时与≥2级毒性增加相关(p值0.063-0.250)。
- 左侧海马平均剂量与放疗后简易精神状态检查评分下降显著相关(p=0.005),右侧海马平均剂量未达统计学显著(p=0.277)。
- 与原始临床计划相比,RapidPlan左侧海马保护模型使左侧海马平均剂量降低43%(p<0.001),且未影响计划靶区覆盖。
关键数值与推荐
- 方案危及器官约束适用于限制常规和短程辅助放化疗的≥2级毒性。
- 推荐常规勾画并使用剂量约束限制海马剂量,以尽量减少神经认知功能下降。
临床怎么用
- 推荐常规勾画海马并使用剂量约束限制海马剂量,以尽量减少接受放化疗的胶质母细胞瘤患者的神经认知功能下降。
- 可使用RapidPlan左侧海马保护模型降低左侧海马平均剂量,且不影响计划靶区覆盖。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: There is no consensus on appropriate organ at risk (OAR) constraints for short-course radiotherapy for patients with glioblastoma. Using dosimetry and prospectively-collected toxicity data from a trial of short-course radiotherapy for glioblastoma, this study aims to empirically examine the OAR constraints, with particular attention to left hippocampus dosimetry and impact on neuro-cognitive decline. METHODS AND MATERIALS: Data was taken from a randomized control trial of 133 adults (age 18-70 years; ECOG performance score 0-2) with newly diagnosed glioblastoma treated with 60 Gy in 30 (conventional arm) versus 20 (short-course arm) fractions of adjuvant chemoradiotherapy (ClinicalTrials.gov Identifier: NCT02206230). The delivered plan's dosimetry to the OARs was correlated to prospective-collected toxicity and Mini-Mental State Examination (MMSE) data. RESULTS: Toxicity events were not significantly increased in the short-course arm versus the conventional arm. Across all OARs, delivered radiation doses within protocol-allowable maximum doses correlated with lack of grade ≥ 2 toxicities in both arms (p < 0.001), while patients with OAR doses at or above protocol limits correlated with increased grade ≥ 2 toxicities across all examined OARs in both arms (p-values 0.063-0.250). Mean left hippocampus dose was significantly associated with post-radiotherapy decline in MMSE scores (p = 0.005), while the right hippocampus mean dose did not reach statistical significance (p = 0.277). Compared to the original clinical plan, RapidPlan left hippocampus sparing model decreased left hippocampus mean dose by 43 % (p < 0.001), without compromising planning target volume coverage. CONCLUSIONS: In this trial, protocol OAR constraints were appropriate for limiting grade ≥ 2 toxicities in conventional and short-course adjuvant chemoradiotherapy for glioblastoma. Higher left hippocampal mean doses were predictive for neuro-cognitive decline post-radiotherapy. Routine contouring and use of dose constraints to limit hippocampal dose is recommended to minimize neuro-cognitive decline in patients with glioblastoma treated with chemoradiotherapy.
引用
- Yang F, Dinakaran D, Heikal AA, et al. Dosimetric predictors of toxicity in a randomized study of short-course vs conventional radiotherapy for glioblastoma. Radiother Oncol. 2022. PMID: 36273738. doi:10.1016/j.radonc.2022.10.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。